Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 331

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 331
---
 under “—Passive Foreign Investment Company Rules,” any gain or loss recognized by a United States
holder on a taxable disposition of Depositary Shares will generally be capital gain or loss and will be long-term capital gain or loss
if the holder’s holding period in such share exceeds one year at the time of the disposition. The deductibility of capital losses
is subject to limitations.

For a cash basis taxpayer,
units of foreign currency received will generally be translated into United States dollars at the spot rate on the settlement date of
the sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the
settlement date of such sale. An accrual basis taxpayer may elect to apply the same rules applicable to cash basis taxpayers with respect
to the sale of ADRs that are traded on an established securities market, provided that the election must be applied consistently from
year to year and cannot be changed without the consent of the IRS. For an accrual method taxpayer who does not make such an election,
units of foreign currency received will generally be translated into United States dollars at the spot rate on the trade date of the sale.
Such an accrual basis taxpayer may recognize foreign currency exchange gain or loss based on currency fluctuations between the trade date
and the settlement date of such sale. In general, any such gain or loss will be ordinary and will be treated as from sources within the
United States for United States foreign tax credit purposes.

| 165 |

<div align='center'>SELLING SHAREHOLDER</div>

This prospectus relates to
the possible resale from time to time by the Selling Shareholder of any or all of the Ordinary Shares (represented by Depositary Shares)
that may be issued by us to the Selling Shareholder under the Purchase Agreement. Such shares of include (i) up to 35,000,000 Purchase
Shares that we may elect, in our sole discretion, to issue and sell to the Selling Shareholder, from time to time from and after the Commencement
Date under the Purchase Agreement; and (ii) up to 875,000 Commitment Shares that may be issued to the Selling Shareholder in connection
with related issuances and sales of Purchase Shares to release the Company of its liability to pay the Commitment Fee as consideration
for the Selling Shareholder’s execution and delivery of the Purchase Agreement.

As used in this prospectus,
the term “Selling Shareholder” includes the Selling Shareholder listed in the table below, and